SAN DIEGO--(BUSINESS WIRE)--Cardium Therapeutics (OTCBB:CDTP) today announced that its Phase 3 product candidate being developed for the potential treatment of myocardial ischemia and associated angina will employ an automated infusion system manufactured for Cardium by Caesarea Medical Electronics Ltd.
